Pharmaceutical Industry Dynamics and Information Strategy

Summary

This study first examines the demographic, economic, clinical, and informational drivers that underpinned and are now transforming the industry. The study also analyzes the glaring data and technological needs the "postblockbuster" environment presents to the pharmaceutical industry and the functional business opportunities those needs represent to industry vendors.

"The pace change in the fundamentals that underpin big pharma's business model is faster and further reaching than at any time in the last 20 years," says LSI consulting manager Charles Firneno. "These changes will alter not only the way drug companies sell their products, but how they formulate strategy throughout the value chain."

Contents

In This Study

Situation Overview

U.S. Demographics and Health Economics
Figure: U.S. National Healthcare Expenditures, 1990, 1994, 1998, 2002, 2006, and 2010
Figure: Worldwide Healthcare Spending per Capita by OECD Country, 1960, 1970, 1980, 1990, and 1999
Figure: Factors Accounting for Growth in Prescription Drug Spending per Capita, 1980�2011
Figure: Prescription Drug Spending Share by Source of Funds, 1965, 1985, and 2000
Epidemiology, Unmet Medical Need, and the Blockbuster Business Model
Pipelines and Therapeutic Transition
Figure: Worldwide Prescription Sales Share by Therapeutic Area, 2004 and 2009
The Changing Selling Environment
Figure: Enormous Pharma Sales and Marketing Expense

Future Outlook

Data and Standards
The Need for Better Clinical Information
The Need for Better Patient Information for Clinical Development
Better Patient and Physician Data for Sales and Marketing
The Possible Alignment of Clinical and Commercial Data

Learn More

Synopsis